Highlights

• Capital Cell’s crowdfunding campaign - Bionure - overfunds with more than €1M and becomes Spain’s largest ever life science equity crowdfunding campaign.

• With this campaign Bionure will now be able to take the next imperative step and begin promising phase-I clinical trials for their novel first-in-class drug for the treatment of multiple sclerosis.

• Following the success of Capital Cell in its country of origin, Spain, with a series of fantastic biotechnology projects funded, the company is currently in the pre-launch phase of expanding into the UK market.

• Capital Cell will be officially launching the new platform at the end of April in association with their partners, the life science angel syndicate group Angels in MedCity

  Details
  

  Huge congratulations are in order for Bionure, a biotech company developing a novel first-in-class drug for the treatment of multiple sclerosis, who are currently overfunding on the Capital Cell crowdfunding platform. With more than €1M raised, this campaign is breaking records by becoming the largest amount raised on a life science equity crowdfunding platform to date, in Spain. Valued at 9,400,000€ and with an estimated ROI of 1400%, Bionure is now at 110% of its funding goal and keeps on rising.

  The capital raised from over 240 investors sharing 9.27% equity in the business will be used by the company to develop BN201, a promising first-in-class drug candidate to halt the development of multiple sclerosis. This disease affects about 2.5 million people worldwide and more than 600,000 in Europe. To date there is no cure.

  This new drug acts as a neuroprotector, preventing the nervous system from damage and reversing the detrimental effects of multiple sclerosis disease. At present, there is no other drug with this dual role of neuroprotection and regeneration, making BN201 a unique product and a hope to multiple sclerosis patients, but also other neurodegenerative diseases such as Parkinsons and Alzheimers.

  After more than six years of research, this late-preclinical drug development company based in Barcelona and California will now be able to take the next big and imperative step: to complete their preclinical phase and begin the BN201 promising phase-I clinical trials.

  As happens with many of the projects raising funds with Capital Cell, Bionure’s campaign ‘#estamosaesto’ (‘we are this close’) is capturing the interest of an heterogeneous ‘crowd’ of investors: from multiple sclerosis patients, relatives and friends, to accredited investors attracted by both the high social impact and the impressive business opportunity it represents (the estimated market for BN201 is about €1.2 billion). “The Capital Cell platform is a great way to expand funding possibilities, reaching investors that we would had never been able to reach”, argues Albert G. Zamora, Bionure CEO.